Trial Profile

Augmentation of Humoral Immunity Using Toll-Like Receptor (TLR) 9 Adjuvanted HBV Surface Antigen to Enhance Anti-HBSAg Response

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary)
Indications Hepatitis B
Focus Adverse reactions
Acronyms BOOST-9

Most Recent Events

25 Jul 2025 study design has been changed from Parallel Assignment to Single Group Assignment, treatment also amended.
25 Jul 2025 Planned number of patients changed from 40 to 10.
25 Jul 2025 Planned End Date changed from 1 Jul 2024 to 1 Apr 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com